Skip to main content Accessibility help
×
Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-16T23:59:17.622Z Has data issue: false hasContentIssue false

27 - Ovarian Hyperstimulation Syndrome

from PART II - INFERTILITY EVALUATION AND TREATMENT

Published online by Cambridge University Press:  04 August 2010

Botros R. M. B. Rizk
Affiliation:
University of South Alabama
Juan A. Garcia-Velasco
Affiliation:
Rey Juan Carlos University School of Medicine,
Hassan N. Sallam
Affiliation:
University of Alexandria School of Medicine
Antonis Makrigiannakis
Affiliation:
University of Crete
Get access

Summary

INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovulation induction, which may cause serious impact on the patient's health, with 0.1–2 percent of the patients developing severe forms of the syndrome (1). This low incidence is increasing worldwide through the expansion of assisted reproductive techniques (ART) (2). Generally speaking, OHSS is a consequence of exogenous gonadotropin/clomiphene citrate administration for ovulation induction – restoring ovulation in anovulatory patients through pharmacological induction of two or three follicles – and more frequently for aggressive controlled ovarian hyperstimulation (COH) used in ART, trying to increase the cohort of follicles achieving maturation in normal ovulatory women. This potentially life-threatening disorder causes massive extracellular exudate accumulation combined with profound intravascular volume depletion and hemoconcentration, accompanied by ovarian enlargement with exaggerated esteroidogenesis and multiple system failure as end point (3).

There are many hormonal variables that are closely related to the pathophysiology of OHSS syndrome, perhaps the most important of which is whether being exogenous or endogenous (e.g., pregnancy derived) (4,5). Elimination of hCG will prevent the full-blown picture of OHSS. In fact, when hCG was replaced for progesterone as luteal support in ovulation induction (OI) or COH, the incidence of OHSS was reduced, maintaining excellent pregnancy rates (6). If hCG is used for luteal phase support, the risk of OHSS is enhanced.

Information

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×